Pembrolizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Pembrolizumab: From Non-Small Cell Lung Cancer to Gingival Fibromatosis
One-Sentence Summary
Pembrolizumab is a PD-1 immune checkpoint inhibitor, originally used for non-small cell lung cancer, lung cancer and metastatic melanoma. The TxGNN model predicts it may be effective for gingival fibromatosis with a very high score, but no clinical trials and no publications support this prediction, so it is a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Non-small cell lung cancer, lung cancer, metastatic melanoma (from the TxGNN knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Fibromatosis, gingival |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Pembrolizumab is a humanized antibody that blocks the PD-1 receptor (PDCD1, CD279) on T cells. This releases the brake on tumour-specific immune responses. It is approved internationally for many cancers, including melanoma and non-small cell lung cancer. Detailed mechanism of action data were not available in the data compiled for this report, but the target is well documented.
The link between the original indications and gingival fibromatosis is weak. Gingival fibromatosis is a benign, non-neoplastic fibrotic overgrowth of the gums, and there is no established rationale for PD-1 blockade in it. The high score appears to be a computational prediction only. Immune checkpoint inhibitors can also cause immune-related adverse events, so potential harm in a benign condition must be weighed carefully.
Other predictions in the list are noted below for context. None has strong supporting evidence:
- Lung hilum carcinoma (rank 4): it lies within the lung cancer spectrum where pembrolizumab is already approved. Evidence is limited to three case reports, so it is largely an extension of the existing indication.
- Lung benign neoplasm (rank 6): the retrieved literature is almost entirely about malignant lung cancer, including several phase 3 RCTs. This is likely a term-mapping artifact and should not be credited to benign neoplasms.
- Lung germ cell tumour (rank 9): the trials found were broad thoracic and solid tumour studies, not germ cell tumour studies. A trial-level eligibility check is needed.
Clinical Trial Evidence
Currently no related clinical trials registered for the predicted indication (gingival fibromatosis).
Literature Evidence
Currently no related literature available for the predicted indication.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14881P | KEYTRUDA Solution for Infusion 25mg/mL | Infusion, solution concentrate | Not stated in the licence record |
| SIN16677P | Pembrolizumab Solution for Infusion 25mg/mL | Infusion, solution concentrate | Not stated in the licence record |
Both licences are valid single-ingredient products, and both are injectable (intravenous infusion) only.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (PD-1 checkpoint inhibitor), not a conventional cytotoxic |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert; immune-related adverse events (endocrine, hepatic, pulmonary, skin, neurologic, muscle) are the main concern |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: 13 interaction records were found.
- Major (3): lenalidomide, pomalidomide, thalidomide.
- Moderate (9): the corticosteroids hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide, prednisolone, prednisone, methylprednisolone and deflazacort.
- The remaining record is the pharmacological target entry (PD-1), not an interacting drug.
- Immune-related adverse events: the literature retrieved for this report describes events such as endocrinopathies, myositis, myocarditis, myasthenia gravis and neurologic toxicity. This is a particular concern for muscle or neurologic predicted indications.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction, gingival fibromatosis, has no clinical trials, no literature and no plausible mechanism. The score of 99.40% is a model output only (L5). Pembrolizumab's strong evidence lies in its existing cancer indications, not in this prediction.
To proceed, the following is needed:
- Mechanistic data (MOA) and a biological rationale for PD-1 blockade in gingival fibromatosis
- Package insert warnings and contraindications from the HSA, which are currently missing and block safety screening
- Singapore approved indication text for the two licences
- A trial-level review of the lung germ cell tumour trial list (44 trials) for germ cell tumour eligibility, and a review of the hilum carcinoma case reports, if a lung-related candidate is to be pursued instead
- A risk-benefit assessment for a benign condition, given immune-related adverse events
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.